The association between iliocostal distance and the number of vertebral and non-vertebral fractures in women and men registered in the Canadian Database For Osteoporosis and Osteopenia (CANDOO)

WP Olszynski*1, G Ioannidis2, RJ Sebaldt3,4, DA Hanley5, A Petrie3, JP Brown6, RG Josse7, TM Murray7, CH Goldsmith4,8, GF Stephenson9, A Papaioannou10 and JD Adachi3

Address: 1Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, 2Charlton Medical Centre, Hamilton, Ontario, Canada, 3Department of Medicine, McMaster University, Hamilton, Ontario, Canada, 4Centre for Evaluation of Medicines, St. Joseph’s Healthcare, Hamilton, Ontario, Canada, 5Department of Medicine, University of Calgary, Calgary, Alberta, Canada, 6Department of Medicine, Laval University, Ste-Foy, Quebec, Canada, 7Department of Medicine, University of Toronto, Toronto, Ontario, Canada, 8Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada, 9Procter & Gamble Pharmaceuticals, Toronto, Ontario, Canada and 10Department of Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada

E-mail: WP Olszynski* - olszynski@webster.sk.ca; G Ioannidis - g.ioannidis@sympatico.ca; RJ Sebaldt - sebaldt@mcmaster.ca; DA Hanley - dahanley@ucalgary.ca; A Petrie - petriea@mcmaster.ca; JP Brown - jacques.brown@crchul.ulaval.ca; RG Josse - josser@smh.toronto.on.ca; TM Murray - tim.murray@utoronto.ca; CH Goldsmith - goldsmith@mcmaster.ca; GF Stephenson - stephenson.gf@pg.com; A Papaioannou - PAPAIOANNOU@HHSC.CA; JD Adachi - jd.adachi@sympatico.ca

*Corresponding author

Abstract

Background: The identification of new methods of evaluating patients with osteoporotic fracture should focus on their usefulness in clinical situations such that they are easily measured and applicable to all patients. Thus, the purpose of this study was to examine the association between iliocostal distance and vertebral and non-vertebral fractures in patients seen in a clinical setting.

Methods: Patient data were obtained from the Canadian Database of Osteoporosis and Osteopenia (CANDOO). A total of 549 patients including 508 women and 41 men participated in this cross-sectional study. There were 142 women and 18 men with prevalent vertebral fractures, and 185 women and 21 men with prevalent non-vertebral fractures.

Results: In women multivariable regression analysis showed that iliocostal distance was negatively associated with the number of vertebral fractures (-0.18, CI: -0.27, -0.09; adjusted for bone mineral density at the Ward’s triangle, epilepsy, cerebrovascular disease, inflammatory bowel disease, etidronate use, and calcium supplement use) and for the number of non-vertebral fractures (-0.09, CI: -0.15, -0.03; adjusted for bone mineral density at the trochanter, cerebrovascular disease, inflammatory bowel disease, and etidronate use). However, in men, multivariable regression analysis did not demonstrate a significant association between iliocostal distance and the number of vertebral and non-vertebral fractures.

Conclusions: The examination of iliocostal distance may be a useful clinical tool for assessment of the possibility of vertebral fractures. The identification of high-risk patients is important to effectively use the growing number of available osteoporosis therapies.
Background
Osteoporosis is one of the most prevalent chronic health conditions. This condition is characterized by low bone mineral density and microarchitectural deterioration of bone tissue leading to increased bone fragility and risk of fracture [1]. It is estimated that approximately 40% of white women and 13% of men 50 years and older will experience at least one clinically recognized hip, spine or distal forearm fragility fracture in their lifetime [2]. These fractures result in physical, psychological and emotional disabilities, and increased pain that can negatively influence quality of life [3,4].

Osteoporosis can be identified early during the course of the disease by diagnostic tests. Bone mineral density measurements provide the single best method for predicting fracture risk [5] but densitometers are occasionally not available and since the pathogenesis of fragility fractures is multifactorial, bone mass is not the only factor that determines risk.

A number of factors have been found to be associated with fragility fractures, they include advanced age, positive family history, height, existing fracture, propensity to falls, and postural instability [5–7]. Unfortunately, our understanding of risk factors is still inadequate and thus, there is a need for further research. The identification of new risk factors should focus on their usefulness in clinical situations such that they are easily measured, applicable to all patients, and contribute prognostic information that is independent of bone mineral density. The size of the gap between the costal margin and the pelvic ridge (iliocostal distance) may be validated to be a surrogate measure for the presence of osteoporosis and/or vertebral fragility fractures and thereby may be a risk factor for future fracture. Hence, the purpose of this cross-sectional study was to examine the association between iliocostal distance and vertebral and non-vertebral fractures in women and men who were seen in a clinical setting.

Methods

Study design
Patient data were obtained from the Canadian Database of Osteoporosis and Osteopenia (CANDOO). CANDOO consists of approximately 10000 patients and involves 8 sites across Canada (Calgary, Saskatoon, Winnipeg, Hamilton, Toronto, Montreal [2 sites], and Quebec City). This database is a prospective registry designed to compile a comprehensive set of osteoporosis-related clinical information [8]. All patients referred to us and seen during the course of routine specialist care were enrolled in CANDOO. Patients data are aggregated using anonymous patient identifiers into a centrally maintained, fully keyed and encoded relational database. In particular, the CANDOO contains electronically stored information regarding basic patient demographics, fracture history, gynecological history, past use of osteoporosis-related drug treatment, drug side effects, past use of corticosteroids and other medications, dietary calcium intake, smoking habits, type and quantity of physical activities, fall history, past medical history and family history including fractures, a self administered osteoporosis health related quality of life instrument, basic laboratory results, and bone density measurements. One database record, with over 400 data fields per patient, is generated for each patient at each clinical visit.

For the current analysis, the database was searched for women and men who had iliocostal distance measurements, and who were seen at the Saskatoon site. The Saskatoon location was chosen because it was the only CANDOO site that recorded iliocostal distance values.

Iliocostal distance measurements and the number of prevalent fractures

Iliocostal distance was defined as the number of cm between the costal margin and the pelvic ridge of a patient, measured in the midaxillary line (figure 1). The measurement was determined by one investigator (WPO) using fingerbreadths (1 finger = 2 cm). All patients were standing during the measurement. Prevalent vertebral and non-vertebral fractures were determined using the CANDOO questionnaire (“Have you ever had any fractures?”). Vertebral fractures may or may not have been confirmed by x-ray. Non-vertebral fractures included the ankle, arm, clavicle, elbow, foot, heel, hand, hip, knee, leg, nose, pelvis, rib, shoulder, sacrum, and wrist. Multivariable linear regression analyses were conducted to determine the relationship between iliocostal distance and the number of vertebral and non-vertebral fractures.

Potential confounding variables

Potential confounding variables collected from CANDOO included age; height; weight; menopausal status; age at menopause; lumbar spine, trochanter, femoral neck, and Ward’s triangle bone mineral density (measurements were made by dual energy x-ray absorptiometry using Hologic or Lunar densitometers); prevalent vertebral fracture status (yes/no); and prevalent non-vertebral fracture status (yes/no); smoking status (never, previously, previously with interruptions, currently, currently with interruptions); family history of fracture (yes/no); number of alcoholic beverages consumed per week (including beer, wine and liquor); number of falls during the last 12 months; dietary calcium intake per day (measured as mg/d and estimated by a food frequency questionnaire); number of minutes spent exercising per week (such as walking, stair climbing, jogging, swimming, bicycling, dancing, skiing and others); current medication use (etidronate, alendronate fluoride, raloxifene, hormone re-
placement or corticosteroids); calcium supplement status (yes/no); vitamin D supplement status (yes/no); and co-morbid conditions (lung disease, liver disease, thyroid disease, cancer, visual problems that are not corrected by eyeglasses or contacts, osteoporosis, inflammatory bowel
disease, epilepsy, coronary disease, cerebrovascular disease, rheumatoid arthritis, diabetes, and kidney failure).

Statistical analysis
All multivariable regression analyses were conducted separately for women and men. We determined regression coefficient estimates as well as 95% confidence intervals (CI) of the estimates. All factors listed in the potential confounding variable section were assessed separately for their association with the number of fractures. Variables with a p-value < 0.2 were included in the multivariable analysis. Variables with a high degree of multicollinearity were removed. Model selection was determined using a stepwise procedure. If necessary, the iliocostal distance variable was force into the final model. All statistical analyses were performed on a Dell computer using the SAS/STAT (version 8.1; SAS Institute Inc., Cary, NC, USA) software package.

Results
A total of 549 patients including 508 women and 41 men participated in this cross-sectional study. Table 1 shows patients' characteristics at study entry for both women and men. A total of 142 women and 18 men had prevalent vertebral fractures, and 185 women and 21 men had prevalent non-vertebral fractures. The number of prevalent vertebral and non-vertebral fractures varied from 0 to 9 and 0 to 7 in women and 0 to 8 and 0 to 6 in men, respectively. Of the patients who sustained a vertebral fracture, 57 (40.1%), 34 (23.9%), 23 (16.2%) and 28 (19.7%) women, and 11 (61.1%), 3 (16.7%), 2 (11.1%), and 2 (11.1%) men had 1, 2, 3, or 4+ vertebral fractures. A total of 112 (60.5%), 48 (25.9%), 16 (8.6%), and 9 (4.9%) women and 10 (47.6%), 7 (33.3%), 1 (4.8%), and 3 (14.3%) men had had 1, 2, 3, or 4+ non-vertebral fractures, respectively. The mean (SD) iliocostal distance for women with a vertebral, non-vertebral and no fracture was 3.49 (1.81) cm, 3.84 (1.69) cm and 4.53 (1.52) cm as compared with 4.22 (1.52) cm, 4.67 (1.43) cm, and 4.77 (1.54) cm for men. Iliocostal distance decreased as the number of vertebral fractures increase in both women and men (table 2). Tables 3 and 4 present univariate regression analysis results in women and men modelled for the number of vertebral and non-vertebral fractures.

Iliocostal Distance
Women
In women, univariate regression analysis revealed a statistically significant negative association between iliocostal distance and the number of vertebral and non-vertebral fractures (Table 3). After adjustments were made for confounding variables, multivariable regression analysis showed that iliocostal distance was negatively associated with the number of vertebral fractures (-0.18, CI: -0.27, -0.09; adjusted for bone mineral density at the Ward’s tri-

Figure 1
Measurement Technique for Iliocostal Distance. Represents iliocostal distance. Iliocostal distance was defined as the number of cm between the costal margin and the pelvic ridge of a patient, measured in the midaxillary line.
Table 1: Baseline characteristics of women and men*

|                      | Women n = 508 | Men n = 41 |
|----------------------|---------------|------------|
| Age-years (SD)       | 61.5 (11.3)   | 57.8 (12.4) |
| Height-cm (SD)       | 160.8 (9.6)   | 174.8 (18.3) |
| Weight-kg (SD)       | 67.8 (14.4)   | 86.2 (22.0) |
| Iliocostal distance-cm (SD) | 4.2 (1.6)   | 4.6 (1.5)   |
| Menopausal status-#post/#pre | 424/78     | NA         |
| Age at menopause-years (SD) | 47.3 (6.8)   | NA         |
| Lumbar spine BMD-g/cm² (SD) | 0.867 (0.165) | 0.918 (0.165) |
| Femoral neck BMD-g/cm² (SD) | 0.664 (0.112) | 0.713 (0.124) |
| Trochanter BMD-g/cm² (SD) | 0.608 (0.107) | 0.676 (0.123) |
| Ward's triangle BMD-g/cm² (SD) | 0.483 (0.133) | 0.471 (0.155) |
| Currently smoking-#  | 64            | 6          |
| Family history of fracture-# | 122        | 12         |
| Alcohol-beverages/week (SD) | 1.4 (3.0)   | 5.5 (8.7)  |
| Number of falls – min to max | 0–12      | 0–4        |
| Calcium intake-mg/d (SD) | 539.0 (435.9) | 553.5 (375.4) |
| Exercise-minutes/week (SD) | 166.7 (165.9) | 187.9 (293.0) |
| Etidronate use-% (%)   | 50 (9.8)      | 3 (7.3)    |
| Alendronate use-% (%)  | 41 (8.1)      | 7 (17.1)   |
| Fluoride use-% (%)     | 2 (0.4)       | 0 (0.0)    |
| Raloxifene use-% (%)   | 9 (1.8)       | 0 (0.0)    |
| Hormone replacement use-% (%) | 146 (28.7) | 0 (0.0)    |
| Corticosteroids use-% (%) | 77 (15.2)   | 8 (19.5)   |
| Calcium supplement use-% (%) | 366 (72.0) | 16 (39.0)  |
| Vitamin D supplement use-% (%) | 173 (34.1) | 10 (24.4)  |
| Lung disease²-% (%)    | 59 (11.6)     | 3 (7.3)    |
| Liver disease²-% (%)   | 13 (2.6)      | 2 (4.9)    |
| Thyroid disease²-% (%) | 69 (13.6)     | 0 (0.0)    |
| Cancer²-% (%)          | 14 (2.8)      | 0 (0.0)    |
| Visual impairment-% (%)| 51 (10.0)     | 2 (4.9)    |
| Osteoporosis-% (%)     | 187 (36.8)    | 13 (31.7)  |
| Inflammatory bowel disease-% (%) | 15 (3.0) | 5 (12.2)   |
| Epilepsy-% (%)         | 7 (1.4)       | 2 (4.9)    |
| Coronary disease-% (%) | 12 (2.4)      | 1 (2.4)    |
| Cerebrovascular disease-% (%) | 19 (3.7) | 1 (2.4)    |
| Rheumatoid arthritis-% (%) | 5 (1.0)   | 0 (0.0)    |
| Diabetes-% (%)         | 18 (3.5)      | 0 (0.0)    |
| Kidney failure-% (%)   | 24 (4.7)      | 0 (0.0)    |

* BMD = bone mineral density; SD = standard deviation; # = number of patients; %= percent of patients; NA = not applicable. ² Lung disease includes asthma, chronic bronchitis and other lung diseases. ³ Liver disease includes cirrhosis, hepatitis and cholangitis. ⁴ Thyroid disease includes hyper, hypo, nodule, and other. ⁵ Cancer includes breast, ovaries, cervix, uterus and colon.

Table 2: Iliocostal distance and the number of vertebral and non-vertebral fractures in women and men

|                      | Women | Men |
|----------------------|-------|-----|
| Vertebral Factures   |       |     |
| 0*                   | 4.53 (1.52) | 4.77 (1.54) |
| 1                    | 3.90 (1.73) | 4.54 (1.57) |
| 2                    | 3.79 (1.75) | 4.00 (2.00) |
| 3                    | 2.91 (1.41) | 4.00 (0.00) |
| 4+                   | 3.75 (2.06) | 3.00 (1.41) |

* Indicates patients without vertebral or non-vertebral fractures.
angle, epilepsy, cerebrovascular disease, inflammatory bowel disease, etidronate use, and calcium supplement use) and for the number of non-vertebral fractures (-0.09, CI: -0.15, -0.03; adjusted for bone mineral density at the trochanter, cerebrovascular disease, inflammatory bowel disease, and etidronate use).

### Table 3: Univariate parameter coefficient estimates and P-values for the association between risk factors and the number of vertebral and non-vertebral fractures in women

| Risk Factor                                      | No. Vertebral Fractures | No. Non-Vertebral Fractures |
|--------------------------------------------------|-------------------------|-----------------------------|
| Age                                              | 0.034                   | 0.018                       |
| Height                                           | -0.012                  | 0.004                       |
| Weight                                           | -0.001                  | 0.002                       |
| Iliocostal distance                              | -0.271                  | -0.115                      |
| Menopausal status                                | 0.516                   | 0.305                       |
| Age at menopause                                 | 0.001                   | -0.006                      |
| Lumbar spine BMD                                 | -0.813                  | -0.722                      |
| Femoral neck BMD                                 | -3.069                  | -1.901                      |
| Trochanter BMD                                   | -3.381                  | -2.415                      |
| Ward's triangle BMD                              | -2.928                  | -1.951                      |
| Prevalent vertebral fractures                    | NA                      | 0.310                       |
| Prevalent non-vertebral fractures                | 0.391                   | 0.003                       |
| Current smoking                                  | 0.018                   | 0.049                       |
| Family history of fracture                       | -0.158                  | 0.121                       |
| Alcohol-beverages/week                           | -0.013                  | -0.012                      |
| No. of falls                                     | -0.004                  | 0.079                       |
| Calcium intake                                   | -0.000                  | 0.000                       |
| Exercise                                         | -0.000                  | -0.000                      |
| Etidronate use                                   | 0.315                   | 0.188                       |
| Alendronate use                                  | 0.250                   | 0.062                       |
| Fluoride use                                     | 0.392                   | 0.843                       |
|Raloxifene use                                    | -0.053                  | 0.167                       |
|Hormone replacement use                           | -0.069                  | -0.001                      |
|Corticosteroids use                               | 0.113                   | 0.564                       |
|Calcium supplement use                            | 0.302                   | 0.107                       |
|Vitamin D supplement use                          | 0.147                   | 0.163                       |
|Lung disease<sup>a</sup>                          | 0.223                   | 0.334                       |
|Liver disease<sup>b</sup>                         | -0.068                  | -0.143                      |
|Thyroid disease<sup>c</sup>                       | -0.185                  | 0.060                       |
|Cancer<sup>d</sup>                                | 0.327                   | 0.190                       |
|Visual impairment                                 | 0.136                   | 0.174                       |
|Osteoporosis<sup>e</sup>                          | -0.109                  | 0.002                       |
|Inflammatory bowel disease                        | -0.634                  | 0.618                       |
|Epilepsy                                          | 1.047                   | -0.175                      |
|Coronary disease                                 | 0.582                   | 0.401                       |
|Cerebrovascular disease                           | 1.042                   | 1.016                       |
|Rheumatoid arthritis                             | 0.083                   | 0.403                       |
|Diabetes                                          | 0.157                   | 0.241                       |
|Kidney failure                                   | 0.115                   | 0.200                       |

* BMD= bone mineral density, NA= not available. <sup>a</sup> Lung disease includes asthma, chronic bronchitis and other lung diseases. <sup>b</sup> Liver disease includes cirrhosis, hepatitis and cholangitis. <sup>c</sup> Thyroid disease includes hyper, hypo, nodule, and other. <sup>d</sup> Cancer includes breast, ovaries, cervix, uterus and colon.

### Men

In men, univariate regression analysis did not demonstrate a significant association between iliacostal distance and the number of vertebral or non-vertebral fractures (Table 4). The iliacostal distance variable remained non-significant following multivariable adjustments modelled for the number of vertebral fractures (-0.12, 95% CI: -0.41, 0.16; adjusted for age and the number of fall during
the past year) and the number of non-vertebral fractures (0.11, 95% CI: -0.18, 0.41; adjusted for number of falls during year, visual problems that are not corrected by eyeglasses or contacts, and height).

**Discussion**

Osteoporosis is under-diagnosed, under-treated and a large number of individuals are unaware that they have this disease. With the emergence of effective treatments it is essential to detect those patients with a vertebral fracture and those with at higher risk of fracture. At present, there is no universally accepted policy for identifying patients with osteoporosis. Clinical risk assessment is an important step in identifying individuals at high risk for osteoporosis and fractures. To our knowledge, the relationships between iliocostal distance and the number of prevalent vertebral and non-vertebral fractures have not been previously reported.

### Table 4: Univariate parameter coefficient estimates and P-values for the association between risk factors and the number of vertebral and non-vertebral fractures in men*

|                        | No. Vertebral Fractures |   | No. Non-Vertebral Fractures |   |
|------------------------|-------------------------|---|-----------------------------|---|
|                        | Coefficient | P-value | Coefficient | P-value | Coefficient | P-value |
| Age                    | 0.035       | 0.072    | -0.005 | 0.788 |
| Height                 | -0.034      | 0.010    | -0.017 | 0.164 |
| Weight                 | 0.007       | 0.523    | 0.015   | 0.155 |
| Iliocostal distance    | -0.259      | 0.095    | -0.037 | 0.796 |
| Lumbar spine BMD       | -2.360      | 0.174    | -0.399 | 0.779 |
| Femoral neck BMD       | -1.378      | 0.511    | -0.106 | 0.953 |
| Trochanter BMD         | -1.728      | 0.410    | -0.822 | 0.646 |
| Ward’s triangle BMD    | -2.138      | 0.196    | 0.275  | 0.846 |
| Prevalent vertebral fractures | NA      | 0.396    | 0.361 |
| Prevalent non-vertebral fractures | -0.090 | 0.851  | NA    |
| Currently smoking      | 0.036       | 0.876    | 0.161  | 0.443 |
| Family history of fracture | -0.538 | 0.330   | -0.647 | 0.184 |
| Alcohol-beverages/week | -0.002      | 0.933    | 0.043  | 0.079 |
| No. of falls           | 0.691       | 0.002    | 0.561  | 0.006 |
| Calcium intake-mg/d    | 0.001       | 0.028    | 0.000  | 0.600 |
| Exercise-min/week      | -0.000      | 0.683    | -0.001 | 0.484 |
| Etidronate use         | 0.259       | 0.574    | -0.180 | 0.665 |
| Alendronate use        | 0.589       | 0.038    | 0.036  | 0.891 |
| Fluoride use           | NA          | NA       | NA     | 0.006 |
|Raloxifene use          | NA          | NA       | NA     | 0.006 |
|Hormone replacement use | NA          | NA       | NA     | 0.006 |
|Corticosteroids use     | -0.479      | 0.286    | 0.000  | 1.000 |
|Calcium supplement use  | -0.014      | 0.972    | -0.370 | 0.279 |
|Vitamin D supplement use| 0.010       | 0.977    | 0.000  | 1.000 |
|Lung disease<sup>a</sup> | -0.921     | 0.315    | 0.000  | 1.000 |
|Liver disease<sup>b</sup> | 1.205     | 0.276    | 1.051  | 0.292 |
|Thyroid disease<sup>c</sup> | NA       | NA       | NA     | 0.006 |
|Cancer<sup>d</sup>      | NA          | NA       | NA     | 0.006 |
|Visual impairment       | -0.257      | 0.810    | 1.635  | 0.082 |
|Osteoporosis            | 1.003       | 0.046    | 0.113  | 0.809 |
|Inflammatory bowel disease | -0.517  | 0.480    | 0.000  | 1.000 |
|Epilepsy                | -0.097      | 0.419    | -1.051 | 0.292 |
|Coronary disease        | -0.875      | 0.574    | 0.000  | 1.000 |
|Cerebrovascular disease | 3.225       | 0.033    | 3.075  | 0.024 |
|Rheumatoid arthritis    | NA          | NA       | NA     | 0.006 |
|Diabetes                | NA          | NA       | NA     | 0.006 |
|Kidney failure          | NA          | NA       | NA     | 0.006 |

<sup>a</sup> BMD= bone mineral density, NA= not available. <sup>b</sup> Lung disease includes asthma, chronic bronchitis and other lung diseases. <sup>c</sup> Liver disease includes cirrhosis, hepatitis and cholangitis. <sup>d</sup> Thyroid disease includes hyper, hypo, nodule, and other. <sup>e</sup> Cancer includes breast, ovaries, cervix, uterus and colon.
Our findings indicated that iliocostal distance is negatively associated with the number of vertebral and non-vertebral fractures in women, such that the shorter the distance the greater number of fractures. Iliocostal distance can be used to identify individuals with vertebral fractures and may be an excellent risk factor for future fractures and should be included in a patient risk profile. This measurement is easy to obtain and assess in a clinical setting, can be measured for all patients, and has a high predictive value for prevalent fracture independent of other known risk factors such as bone mineral density. From our clinical experience, healthy adults have an iliocostal distance of approximately 6 cm.

Vertebral fractures are a well-recognized consequence of postmenopausal bone loss and are the most common osteoporotic fractures [9]. It is estimated that less than one third of all vertebral fractures are clinically diagnosed [10]. A common explanation is that fractures are frequently asymptomatic and patients who suffer them are not prompted to seek medical attention. Furthermore, physicians may not be identifying prevalent fractures among their patients. The early identification of a vertebral fracture is essential. It has been shown that women who develop a vertebral fracture are at increased risk for an additional vertebral fracture [11] and that 20% of women will experience a subsequent fracture within the one year following the first vertebral fracture [12]. Moreover, there is growing evidence that all vertebral fractures are associated with adverse health consequences. Nevitt et al. [13] have found that back pain, functional limitation and disability days are associated with fractures. Among this large cohort of women 65 years of age and older, patients who sustained fractures were 2 to 3 fold more likely to experience more back pain and disability when performing back-dependent activities of daily living as compared with the unaffected comparison group. Likewise, fracture patients were at higher risk of experiencing limited activity days and days confined to bed. Kado et al. [14] observed that women who developed new fractures over a duration of 8 years had a 23% increased risk of mortality. This study also found a dose response effect such that mortality increased with the number of fractures. Accordingly, it is important that physicians recognize patients at risk for vertebral fracture or patients that have sustained fractures.

It is not surprising that iliocostal distance measurements in women were also associated with non-vertebral fractures. Vertebral fractures are early indicators of other osteoporotic fractures [15–17]. For instance, it has been shown that women who have a prevalent vertebral fracture have an increased relative risk (RR) of a subsequent fracture at the wrist (RR = 1.4), hip (RR = 2.3), and all non-spinal sites (RR = 1.8) as compared with unaffected women [11].

Our results showed that iliocostal distance values were associated with fractures in women but not in men. The apparent differences between women and men are difficult to explain; however, others have found gender differences in risk factors for increased bone loss in an elderly population [18]. Nonetheless, due to the low number of men (n = 41) recruited in this study (and the low statistical power) caution should be taken in the interpretation of the results. Further research will need to be conducted in men to confirm or dispute our findings.

Several features of the study are unique, and thus reinforce our conclusions. For example, all participants were “real world” patients who were seen for osteoporosis in a tertiary care setting and thus represent a homogeneous group. Other strengths included the large sample size of women, the careful delineation of potential confounding variables studied, and the wealth of data available about the study cohort. Nonetheless, our study is not without limitations. The study was cross-sectional in design and partially depended on information obtained by recall. Although adjustments were made for several variables, it remains possible that other, unknown determinants of fracture confound the observed associations. Due to the lack of data, no distinction was made between lumbar and thoracic fractures. Moreover, only one investigator assessed iliocostal distance using fingerbreadth as the measurement device, as such future validation of this useful clinical tool in terms of inter-rater reliability is recommended. Not all spinal fractures were confirmed by x-ray. X-rays were performed only in patients with back pain. Therefore, subclinical vertebral fractures may have developed. As a consequence, the actual association between iliocostal distance and the number of vertebral fractures may have been underestimated. The relationship between iliocostal distance and vertebral fractures should be tested in those patients with subclinical fractures.

Conclusions

At present, only a small number of patients at high risk for fracture are currently recognized. Indeed, vertebral fractures often do not produce symptoms, so that many individuals with fractures will not seek medical attention for the problem. However, all vertebral fractures, whether symptomatic or radiographically identified, are associated with increased mortality and morbidity. The challenge for primary care physicians is to prevent, diagnose, and treat osteoporosis as early as possible. Thus, identification is the first step in osteoporosis management. The examination of iliocostal distance may be an excellent clinical opportunity to identify osteoporotic individuals for referral for diagnosis, preventive counseling and management. The identification of high-risk patients is important to effectively use the growing number of available osteoporosis therapies. Longitudinal studies will need to be...
conducted to determine the association between changes in iliacostal distance measurements and fractures.

**Competing interests**
None declared.

**Authors’ Contributions**
WPO participated in the design of the study, critical review of the manuscript; GI participated in the design of the study, drafted the manuscript and statistical analysis; RJS participated in the design of the study, critical review of the manuscript; JPB: critical review of the manuscript; RGJ: critical review of the manuscript TMM: critical review of the manuscript; JDA critical review of the manuscript; RJS participated in the design of the study, critical review of the manuscript; AP: critical review of the manuscript; DAH critical review of the manuscript; GI participated in the design of the study, critical review of the manuscript and statistical analysis; WPO participated in the design of the study, critical review of the manuscript.

All authors gave final approval of the manuscript.

**References**
1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646-650
2. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL: Perspective how Many women have osteoporosis? J Bone Miner Res 1992, 7:1005-1010
3. Greendale GA, Barrett-Connor E, Ingles S, et al: Late physical and functional effects of osteoporotic fractures in women: the Rancho Bernardo study. J Am Geriatr Soc 1995, 43:955-961
4. Cooper C: The crippling consequences of fractures and their impact on quality of Life. Am J Med 1997, 103:125-195
5. Josse R, Hanley D, Lintle B: New tools new criteria. Osteoporosis Update 1999, 3:2-7
6. Versluis RG, Papapoulos SE, de Bock GH, et al: Clinical risk factors as predictors of postmenopausal osteoporosis in general practice. Br J Gen Pract 2001, 51:806-10
7. Cummings SR, Nevitt MC, Browner WS, et al: Risk factors for hip fracture in white women. N Engl J Med 1995, 322:767-773
8. Sebaldt Rj, Adachi JD: Canadian database of osteoporosis and osteopenia patients (CANDOO). Canadian organization for the advancement of computers in healthcare proceedings 1996, 21:41-44
9. Ross PD: Clinical consequences of vertebral fractures. Am J Med 1997, 103(suppl):305-435
10. Cooper C, Atkinson Ej, O’Fallon WM, Melton LJ: Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992, 7:221-227
11. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739
12. Lindsay R, Silverman SL, Cooper C, et al: Risk of new vertebral fractures in the year following a fracture. JAMA 2001, 285:320-323
13. Nevitt MC, Thompson DE, Black BM, et al: Effect of alendronate on limited activity days and bed disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 2000, 160:77-85
14. Kado DM, Browner WS, Palermo L, et al: Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 1999, 1215:1220
15. Ross PD, Davis JW, Epstein RS, Wasnich RD: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919-923
16. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD: Predicting vertebral fracture incidence from prevalent fractures and bone mineral density among non-black, osteoporotic women. Osteoporos Int 1993, 3:120-126
17. Ismail AA, Cockerill W, Cooper C, et al: Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int 2001, 12:85-90
18. Burger H, de Laet CEDH, van Daele PLA, et al: Risk factors for increased bone loss in elderly population. The Rotterdam Study. Am J Epidemiol 1998, 147:871-879

**Pre-publication history**
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/3/22/prepub